Bristol Myers Squibb reports that its phase II QUINTESSENTIAL trial of arlocabtagene autoleucel met the main goal in adults with relapsed and refractory multiple myeloma.
Adam Nicolson became the first person in Scotland to receive CAR-T cell therapy for myeloma after exhausting all other options. Now in remission, his case is driving new research into the therapy’s potential for autoimmune diseases.
Arovella Therapeutics has received FDA clearance to begin Phase 1 clinical testing of its allogeneic cell therapy ALA-101 targeting CD19-positive blood cancers.
